OL

Olivier Litzka

Partner at Andera Partners

Germany

Overview 

Olivier Litzka is a Partner at Andera Partners, specializing in Life Sciences investments in Germany. With a background in biotechnology and private equity, he has successfully invested in numerous companies at various stages such as SciRhom (Series A) and Arvelle Therapeutics (Series A). Litzka's career highlights include leading investments in innovative life science companies like T-knife (Series B) and Vivoryon Therapeutics (Series Unknown), showcasing his expertise in biopharmaceuticals and venture capital within the industry.

Work Experience 

AP

Andera Partners

  • Partner

    2018 - Current

    ANDERA PARTNERS (formerly EdRIP, Edmond de Rothschild Investment Partners) is a leading European Private Equity House, managing more than €2 bn in Life Sciences Venture Capital, Growth Capital, LBO, and Sponsorless Mezzanine Olivier is a partner in Andera Partners' life sciences franchise constituted by its BioDiscovery funds. The team manages around Euro 700 m of assets. The latest fund BioDiscovery 5 was closed in January 2018 at Euro 345 m. As its predecessors, it targets investments in biotech and medtech companies in Europe and the US.

E

EdRIP

  • Partner

    2006 - 2018

    Partner in the Life Science fund franchise BioDiscovery. 380 m€ under management via funds BioDiscovery I, II, III and IV. Paris based and investing in Europe and US.

3G

3i Group plc

  • Director

    2000 - 2006

    - member of the 3i healthcare practice - focussing purely on investments into biotechnology, biopharma, medtech, healthcare companies - responsible for the French market but involved in European and US wide investments and investment projects - member of boards in investee companies

Mercer Management Consulting

  • Associate

    1998 - 2001

LU

Ludwig-Maximilians Universität München

  • Research Scientist

    1994 - 1998

    Department of Molecular Microbiology

Investments 

SciRhom

Series A

Total funding: $68M

MMI

Series A

Total funding: $210M

Ariceum Therapeutics

Series A

Total funding: $52M

JenaValve Technology

Series C

Total funding: $270M

Articles About Olivier

Relevant Websites